Polish respiratory society guidelines for chronic obstructive pulmonary disease;Zalecenia Polskiego Towarzystwa Chorób Płuc dotycza{ogonek}ce rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc

Pneumonologia i Alergologia Polska

Volumn 82, Issue 3, 2014, Pages 227-263

  Śliwiński, Paweł ^a   Górecka, Dorota ^a   Jassem, Ewa ^a   Pierzchała, Władysław ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL COMPETENCE; CLINICAL PRACTICE; HUMAN; ORGANIZATION AND MANAGEMENT; POLAND; PRACTICE GUIDELINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONOLOGY; STANDARDS; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; CLINICAL COMPETENCE; HUMANS; POLAND; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE;

EID: 84901400756     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: 10.5603/PiAP.2014.0030     Document Type: Article

References (228)

1. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004; 23: 932-946.
2. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org/.
3. Halbert R.J., Natoli J.L., Gano A., Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 2006; 28: 523-532.
4. Jemal A., Ward E., Hao Y., Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-1259.
5. Murray C.J.L., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
6. Niepsuj G., Kozielski J., Niepsuj K., Przewlekła obturacyjna choroba płuc wśród mieszkańców Zabrza. Wiad. Lek. 2002; 55 (supl. 1): 354-359.
7. Nizankowska-Mogilnicka E., Mejza F., Buist A.S., Prevalence of COPD and tobacco smoking in Malopolska region- -results from the BOLD study in Poland. Pol. Arch. Med. Wewn. 2007; 117: 402-410.
8. Bednarek M., Maciejewski J., Woźniak M., Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax 2008; 63: 402-407.
9. Rocznik demograficzny 2010, Główny Urza{ogonek}d Statystyczny, 2011.
10. Korzeniewska-Koseła M. (red.). Gruźlica i choroby układu oddechowego w Polsce. Instytut Gruźlicy i Chorób Płuc, Warszawa 2010.
11. Young R.P., Hopkins R., Eaton T.E. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur. Respir. J. 2007; 30: 616-622.
12. Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. J. Respir Crit. Care Med. 1996; 153: 1530-1535.
13. Burrows B., Kettel L.J., Niden A.H., Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N. Engl. J. Med. 1972; 286: 912-918.
14. Blanc P.D., Menezes A.M., Plana E., Occupational exposures and COPD: an ecological analysis of international data. Eur. Respir. J. 2009; 33: 298-304.
15. Hnizdo E., Sullivan P.A., Bang K.M., Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition examination survey. Am. J. Epidemiol. 2002; 156: 738-746.
16. de Leeuw F., Horálek J. Assessment of the Health Impacts of Exposure to PM2.5 at a European Level. Bilthoven, European Topic Centre on Air and Climate Change, 2009. Available from: http://acm.eionet.europa.eu/reports/ETCACC_TP_2009_1_European_PM2.5_HIA
17. Schindler C., Keidel D., Gerbase M.W., Improvements in PM1O exposure and reduced rates of respiratory symptoms in a cohort of Swiss adults (SAPALDIA). Am. J. Respir. Crit. Care Med. 2009; 179: 579-587.
18. Barker D.J.P., Godfrey K.M., Fall C.H.D., Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. Br. Med. J. 1991; 303: 671-675.
19. Rijcken B, Schouten JP, Weiss ST, Speizer FE, vander Lende R. The relationship of nonspecific bronchial responsiveness to respiratory symptoms in a random population sample. Rev. Respir. Dis. 1987; 136: 62-68.
20. Silva G.E., Sherrill D.L., Guerra S., Barbee R.A. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126: 59-65.
21. Lange P., Parner J., Vestbo J., Schnohr P., Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 1998; 339: 1194-1200.
22. de Marco R., Accordini S., Marcon A., Risk factors for chronic obstructive pulmonary diseasi in a European cohort of young adults. Am. J. Respir. Crit. Care Med. 2011; 183: 891-897.
23. Stoller J.K., Aboussouan L.S. α1-antitrypsin deficiency. Lancet 2005; 365: 2225-2236.
24. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanism. Eur. Respir. J. 2003; 22: 672-688.
25. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur. J. Pharmacol. 2001; 429: 195-207.
26. Barnes P.J. Macrophages as orchestrators of COPD. J. COPD 2004; 1: 59-70.
27. O'Shaughnessy T.C., Ansari T.W., Barnes N.C., Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8 + T lymphocytes with FEV1. Am. J. Respir. Crit. Care Med. 1997; 155: 852-857.
28. Thompson A.B., Daughton D., Robbins R.A., Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am. Rev. Respir. Dis. 1989; 140: 1527-1537.
29. Hogg J.C., Chu F., Utokaparch S., The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645-2653.
30. Hardie J.A., Buist A.S., Vollmer W.M., Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur. Respir. J. 2002; 20: 1117-1122.
31. Vollmer W.M., Gíslason P., Burney P., Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J 2009; 34: 588-597.
32. Quanjer Ph.H., Tammeling G.J., Cotes J.E., Lung volumes and forced ventilatory flows. Official statement of the European Respiratory Society. Eur. Respir. J. 1993; (supl. 16): 5-40.
33. Falaschetti E., Laiho J., Primatesta P., Purdon S. Prediction equations for normal and low lung function from the Health Survey for England. Eur. Respir. J. 2004; 23: 456-463.
34. Jones P.W., Harding G., Berry P., Wiklund I., Chen W.H., Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34: 648-654.
35. Mackay A.J., Donaldson G.C., Patel A.R., Jones P.W., Hurst J.R., Wedzicha J.A. Utility of the COPD Assessment Test (CAT) to Evaluate Severity of COPD Exacerbations. Am. J. Respir. Crit. Care Med. 2012; 185: 1218-1224.
36. Augusti A., Calverley P., Celli B., Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.
37. Miravitlles M., Soriano J.B., Garcia-Rio F., Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64: 863-868.
38. Miller M.R., Hankinson J., Brusasco V., Standardisation of spirometry. Eur. Respir. J. 2005; 26: 319-338.
39. Jones P., Tabberer M., Chen W.-H. Creating scenarios of the impact of COPD and their relationship to COPD assessment test (CATTM) scores. BMC Pul. Med. 2011; 11: 42.
40. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1: 1645-1648.
41. Kesten S., Celli B., Decramer M., Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from UPLIFT trial. Respir. Res. 2011; 12: 129-138.
42. Vestbo J., Edwards L.D., Scanlon P.D., Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 2011; 365: 1184-1192.
43. Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung func tion decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
44. Rennard S.I., Vestbo J. Natural histories of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2008; 5: 878-883.
45. Celli B.R., Cote C.G., Marin J.M., The body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005-1012.
46. Anthonisen N.R., Connett J.E., Murray R.P. for the Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care. Med. 2002; 166: 675-679.
47. Anthonisen N.R., Skeans M.A., Wise R.A., Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233-239.
48. Kohansal R., Soriano J.B., Agusti A. Investigating the natural history of lung function: facts, pitfalls, and opportunities. Chest 2009; 135: 1330-1341.
49. Zieliński J., Bednarek M., Górecka D., w imieniu grupy "Poznaj wiek swoich płuc": Narodowy Program Wczesnego Rozpoznawania i Profilaktyki POChP w latach 2000-2002. Pneumonol. Alergol. Pol. 2005; 73: 116-121.
50. Buffels J., Degryse J., Heyrman J., Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest 2004; 125: 1394-1399.
51. Kohansal R., Martinez-Camblor P., Agusti A., The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J. Respir. Crit. Care Med. 2009; 180: 3-10.
52. Lin K., Watkins B., Johnson T., Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 2008; 148: 535-543.
53. West R., McNeill A., Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000; 55: 987-999.
54. Górecka D., Bednarek M., Nowiński A., Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123: 1916-1923.
55. Bednarek M., Gorecka D., Wielgomas J., Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61: 869-873.
56. Silagy C., Lancaster T., Stead L., Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004; (3): CD000146. Review. Update in: Cochrane Database Syst Rev. 2008; (1): CD000146.
57. Jorenby D.E., Leischow S.J., Nides M.A., A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999; 340: 685-691.
58. Tashkin D., Kanner R., Bailey W., Smoking cessation in patients with chronic obstructive pulmonary disease: a double- blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575.
59. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2008 Issue 3: CD006103.
60. Tashkin D.P., Rennard S., Hays J.T., Ma W., Lawrence D., Lee T.C. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139: 591-599.
61. West R., Zatonski W., Cedzynska M., Placebo-controlled trial of cytisine for smoking cessation. N. Engl. J. Med. 2011; 365: 1193-1200.
62. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir. Care 2008; 53: 1217-1222.
63. Torres-Duque C., Maldonaldo D., Perez-Padilla R., on behalf of the Forum of International Respiratory Studies (FIRS) Task Force on Health Effects of Biomass Exposure. Biomass fuels and respiratory diseases: a review of evidence. Proc. Am. Thorac. Soc. 2008; 5: 577-590.
64. Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006 25; (1): CD002733.
65. Schembri S., Morant S., Winter J.H., MacDonald T.M. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax 2009; 64: 567-572.
66. Schenkein J.G., Nahm M.H., Dransfield M.T. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest 2008; 133: 767-774.
67. Walters J.A., Smith S., Poole P., Granger R.H., Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2010 Nov 10; (11): CD001390.
68. Zalecenia Polskiego Towarzystwa Chorób Płuc rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc (POChP). Pneumonol. Alergol. Pol. 2010; 78: 1-45.
69. Rodrigo G.J., Nannini L.J., Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 2008; 133: 1079-1087.
70. Decramer M., Celli B., Kesten S., Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
71. O'Donnel D.E., Fluege T., Gerken F., Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832-840.
72. Kesten S., Casaburi R., Kukafka D., Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2008; 3: 127-136.
73. Kerwin E.M., D'Urzo A., Gelb A.F., Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9: 90-101.
74. Jones P.W., Agusti A., Bateman E.D., Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN. Eur. Respir. J. 2012; 40: 830-836.
75. D'Urzo A., Ferguson G.T., van Nord J.A., Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res. 2011; 12: 156-168.
76. Kerwin E., Hebert J., Gallagher N., Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J. 2012; 40: 1106-1114.
77. Maltais F., Celli B., Casaburi R., Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir. Med. 2011; 105: 580-587.
78. Beeh K.M., Singh D., Di Scala L., Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 7: 503-513.
79. Fuhr R., Magnussen H., Sarem K., Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate-to-severe COPD. Chest 2012; 141: 745-752.
80. Tashkin D.P., Celli B., Senn S., A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554.
81. Tashkin D.P. Impact of tiotropium on the course of moderate- to-very severe chronic obstructive pulmonary disease: the UPLIFT trial. Expert Rev. Respir. Med. 2010; 3: 279-289.
82. Wedzicha J.A., Calverley P.M., Seemungal T.A., The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19-26.
83. Vogelmeier C., Hederer B., Gleb T., Tiotropium versus salmeterol for prevention of exacerbation of COPD. N. Engl. J. Med. 2011; 364: 1093-1101.
84. Troosters T., Celli B., Lystig T., Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur. Respir. J. 2010; 36: 65-73.
85. Morice A.H., Celli B., Kesten S., COPD In young patients: a prespecified analysis of the four-year trial of tiotropium (UPLIFT). Respir. Med. 2010; 104: 1659-1667.
86. Celli B., Decramer M., Leimer I., Cardiovascular safety of tiotropium in patient with COPD. Chest 2010; 137: 20-30.
87. Wise R.A., Anzueto A., Cotton D., Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369: 1491-1501.
88. Breekveldt-Postma N., Koerselman J., Erkens J., Enhanced persistence with tiotropium compared with other respiratory drugs In COPD. Respir. Med. 2007; 101: 1398-1405.
89. Calverley P., Pauwels R., Vestbo J., Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
90. Szafranski W., Cukier A., Ramirez A., Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81.
91. Calverley P.M., Kuna P., Monsó E., Beclomethasone/ formoterol in the management of COPD: a randomised controlled trial. Respir. Med. 2010; 104: 1858-1868.
92. Dahl R., Chung K.F., Buhl R., INVOLVE (Indacaterol: Value In COPD: Long Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily LABA, indacaterol versus twice-daily LABA formoterol in COPD. Thorax 2010; 65: 473-479.
93. Kornmann O., Dahl R., Centanni S., for the INLIGHT-2. Indacaterol efficacy evaluation using 150 mg doses with COPD. Patients study investigators. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur. Respir. J. 2010; 37: 273-279.
94. Barr R.G., Rowe B.H., Camargo C.A. Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta- analysis of randomised trials. BMJ 2003; 327: 643-649.
95. Tashkin D.P., Litner M., Andrews Ch.P., Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD. A placebo-controlled trial. Respir. Med. 2008; 102: 478-487.
96. Bateman E.D., Ferguson G.T., Barnes N., Dual bronchodilatation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42: 1484-1494.
97. Wedzicha J.A., Decramer M., Ficker J.H., Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glicopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1: 199-209.
98. Mills E.J. Druyts E. Ghement I. Puhan M.A. Pharmacotherapies for chronic obstructive pulmonary disease; a multiple treatment comparison meta-analysis. Clin. Epidemiol. 2011; 28: 107-129.
99. Alsaeedi A., Sin D.D., McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. 2002; 113: 59-65.
100. Szafranski W., Cukier A., Ramirez A., Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81.
101. Calverley P.M., Anderson J.A., Celli B., Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789.
102. Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036.
103. Nannini L., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; (4): CD003794.
104. Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; (4): CD006829.
105. Celli B.R., Thomas N.E., Anderson J.A., Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178: 332-338.
106. Jenkins C.R., Jones P.W., Calverley P.M.A., Efficacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10: 59.
107. Singh D., Brooks J., Hagan G., Cahn A., O'Connor B.J. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592-598.
108. Aaron S.D., Vandemheen K.L., Fergusson D., Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-555.
109. Welte T., Miravitlles M., Hernandez P. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2009; 180: 741-750.
110. Calverley P.M., Sanchez-Toril F., McIvor A., Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 176: 154-161.
111. Calverley P.M., Rabe K.F., Goehring U.M., Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694.
112. Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L., Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
113. Poole P., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systemic Reviews. 2006; Issue 3: Art No: CD001287.
114. Seemungal T.A., Wilkinson T.M., Hurst J.R., Perera W.R., Sapsford R.J., Wedzicha J.A. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 2008; 178: 1139-1147.
115. Albert R.K., Connett J., Bailey W.C., COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365: 689-698.
116. Zieliński J., Tobiasz M., Hawryłkiewicz I., Śliwiński P., Pałasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients. Chest 1998; 113: 65-70.
117. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391-398.
118. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-686.
119. Pływaczewski R., Śliwiński P., Nowiński A., Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy. Chest 2000; 117: 679-683.
120. Skwarski K. Nocna hipoksemia i zaburzenia rytmu serca u chorych z przewlekła{ogonek} obturacyjna{ogonek} choroba{ogonek} płuc. Pol. Arch. Med. Wewn. 1989; 81: 283-294.
121. Śliwiński P., Łagosz M., Górecka D., Zieliński J. The adequacy of oxygenation in COPD patients undergoing long-term oxygen therapy assessed by pulse oximetry at home. Eur. Respir. J. 1994; 7: 274-278.
122. Goldstein R.S., Ramcharan C., Bowes G., Effect of supplemental oxygen on gas exchange in patients with severe obstructive lung disease. N. Engl. J. Med. 1984; 310: 425-429.
123. O'Donnell D.E., Sain D.J., Webb K.A. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am. J. Respir. Crit. Care Med. 1997; 155: 530-535.
124. Somfay A., Porszasz J., Lee S.M., Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patents. Eur. Respir. J. 2001: 18: 77-84.
125. Gong H., Jr. An air travel and oxygen therapy in cardiopulmonary patients. Chest 1992; 101: 1104-1113.
126. Gong H., Jr., Taskhin D.P., Lee E.Y., Simmons M.S. Hypoxia altitude simulation test. Evaluation of patients with chronic airway obstruction. Am. Rev. Respir. Dis. 1984; 130: 980-986.
127. Berg B.W., Dislard T.A., Rajagopal K.R., Mehm W.J. Oxygen supplementation during air travel in patients with chronic obstructive lung disease. Chest 1992; 10: 638-641.
128. Walker J., Kelly P.T., Beckert L. Air line policy for passengers requiring supplemental in-fligh oxygen. Respirology 2009; 14: 589-594.
129. Mehran R.J., Deslauriers J. Indication for surgery and patient work-up for bullectomy. Chest Surg. Clin. N. Am. 1995; 5: 717-734.
130. Hughes J.A., MacArthur A.M., Hutchison D.C., Hugh-Jones P. Long term changes in lung function after surgical treatment of bullous emphysema in smokers and ex-smokers. Thorax 1984; 39: 140-142.
131. Laros C.D., Gelissen H.J., Bergstein P.G., Bullectomy for giant bullae in emphysema. J. Thorac. Cardiovasc. Surg. 1986; 91: 63-70.
132. Flaherty K.R., Kazerooni E.A., Curtis J.L., Short-term and long-term outcomes after bilateral lung volume reduction surgery: prediction by quantitative CT. Chest 2001; 119: 1337-1346.
133. Gelb A.F., McKenna R.J. Jr, Brenner M., Lung function 5 yr after lung volume reduction surgery for emphysema. Am. J. Respir. Crit. Care Med. 2001; 163: 1562-1566.
134. Naunheim K.S., Wood D.E., Mohsenifar Z., Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann. Thorac. Surg. 2006; 82: 431-443.
135. Hamacher J., Russi E.W., Weder W. Lung volume reduction surgery: a survey on the European experience. Chest 2000; 117: 1560-1567.
136. Sciurba F.C., Emst A., Herth F.J., A randomized study of endobronchial valves for advanced emphysema. N. Engl. J. Med. 2010; 363: 1233-1244.
137. Hosenpud J.D., Bennett L.E., Keck B.M., The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report -1998. J. Heart Lung Transplant. 1998; 17: 656-668.
138. Maurer J.R., Frost A.E., Estenne M., Higenbottam T., Glanville A.R. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 1998; 66: 951-956.
139. Gosselink R., Troosters T., Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am. J. Respir. Crit. Care Med. 1996; 153: 976-980.
140. Goldstein R.S., Gort E.H., Stubbing D., Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344: 1394-1397.
141. Troosters T., Casaburi R., Gosselink R., Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 19-38.
142. Puhan M.A, Chandra D., Mosenifar Z., National Emphysema Treatment Trial (NETT) Research Group. The minimal important difference of exercise tests in severe COPD. Eur. Respir. J. 2011; 37: 784-790.
143. O'Donnell D.E., McGuire M., Samis L., The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am. J. Respir. Crit. Care Med. 1995; 152: 2005-2013.
144. Casaburi R., Kukafka D., Cooper C.B., Witek T.J. Jr., Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-817.
145. Behnke M., Taube C., Kirsten D., Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. Respir. Med. 2000; 94: 1184-1191.
146. Troosters T., Gosselink R., Decramer M. Short and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease a randomized trial. Am. J. Med. 2000; 109: 207-212.
147. Puhan M.A., Gimeno-Santos E., Scharplatz M., Troosters T., Walters E.H., Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011 Oct 5; (10): CD005305.
148. Finnerty J.P., Keeping I., Bulfough I., Jones J. The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: a randomized controlled trial. Chest 2001; 119: 1705-1710.
149. Green R.H., Singh S.J., Williams J., Morgan M.D. A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2001: 58: 143-145.
150. Gibson P.G., Wlodarczyk J.H., Wilson A.J., Sprogis A. Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J. Qual. Clin. Pract. 1998; 18: 125-133.
151. Mahler D.A. Pulmonary rehabilitation. Chest 1998; 113: 263S-268S.
152. Bernard S., Whittom F., Leblanc P., Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1990; 159: 896-901.
153. Smith K., Cook D., Guyatt G.H., Respiratory muscle training in chronic airflow limitation: a met-analysis. Am. Rev. Respir. Dis. 1992; 145: 533-539.
154. Lotters F., van Tol B., Kwakkel G., Gosselink R. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur. Respir. J. 2002; 20: 570-576.
155. Brochard L., Mancebo J., Wysocki M., Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 1995; 333: 817-822.
156. Hillberg R.E., Johnson D.C. Noninvasive ventilation. N. Engl. J. Med. 1997; 337: 1746-1752.
157. Muir J.F., Cuvelier A., Verin E., Noninvasive mechanical ventilation and acute respiratory failure: indications and limitations. Monaldi Arch. Chest. Dis. 1997; 52: 56-59.
158. Chandra D., Stamm J.A., Taylor B., Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States,1998-2008. Am. J. Respir. Crit. Care Med. 2012; 185: 152-159.
159. Elliott M.W. Noninvasive ventilation in chronic ventilatory failure due to chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 20: 511-514.
160. Consensus conference report. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation. Chest 1999; 116: 521-534.
161. Clini E., Sturani C., Rossi A., The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur. Respir. J. 2002; 20: 529-538.
162. Pingleton S.K. Invasive mechanical ventilation in exacerbations of chronic obstructive pulmonary disease. Monaldi Arch. Chest Dis. 1998; 53: 337-342.
163. Purro A., Appendini L., De Gaetano A., Physiologic determinants of ventilator dependence in long-term mechanically ventilated patients. Am. J. Respir. Crit. Care Med. 2000; 161: 1115-1123.
164. Nava S., Rubini F., Zanotti E., Survival and prediction of successful ventilator weaning in COPD patients requiring mechanical ventilation for more than 21 days. Eur. Respir. J. 1994; 7: 1645-1652.
165. Nevins M.L., Epstein S.K. Predictors of outcome for patients with COPD requiring invasive mechanical ventilation. Chest 2001; 119: 1840-1849.
166. Esteban A., Anzueto A., Alia I., How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am. J. Respir. Crit. Care Med. 2000; 161: 1450-1458.
167. Pauwels R., Calverley P., Buist A.S., COPD exacerbations: the importance of a standard definition. Respir. Med. 2004; 98: 99-107.
168. Caramori G., Adcock I.M., Papi A. Clinical definition of COPD exacerbations and classification of their severity. South Med. J. 2009; 102: 277-282.
169. Hurst J.R., Vestbo J., Anzueto A., Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128-1113.
170. Vestbo J., Edwards L.D., Scanlon P.D., Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 2011; 365: 1184-1192.
171. Kesten S., Celli B., Decramer M., Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial. Respir. Res. 2011; 12: 129-138.
172. Jahnz-Rózyk K., Targowski T., From S., Koszty przewlekłej obturacyjnej choroby płuc u pacjentów leczonych w ramach specjalistycznej opieki ambulatoryjnej w Polsce. Pneumonol. Alergol. Pol. 2011; 79: 333-342.
173. Anthonisen N.R., Manfreda J., Warren C.P., Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.
174. Woodhead M., Blasi F., Ewig S., Guidelines for the management of adult lower respiratory tract infections - Summary. Clin. Microbiol. Infect. 2011; 17 (supl. 6): 1-24.
175. Cazzola M., MacNee W., Martinez F.J., American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31: 416-469.
176. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786-796.
177. Hurst J.R., Donaldson G.C., Wilkinson T.M., Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur. Respir. J. 2005; 26: 846-852.
178. Seemungal T., Harper-Owen R., Bhowmik A., Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 1618-1623.
179. Yang C.Y., Chen C.J. Air pollution and hospital admissions for chronic obstructive pulmonary disease in a subtropical city: Taipei, Taiwan. J. Toxicol. Environ. Health A. 2007; 70: 1214-1219.
180. Linaker C.H., Coggon D., Holgate S.T., Personal exposure to nitrogen dioxide and risk of airflow obstruction in asthmatic children with upper respiratory infection. Thorax 2000; 55: 930-933.
181. Holguin F., Folch E., Redd S.C., Mannino D.M. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005-2011.
182. Tillie-Leblond I., Marquette C.H., Perez T., Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann. Intern. Med. 2006; 144: 390-396.
183. Smeeth L., Cook C., Thomas S., Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006; 367: 1075-1079.
184. Tokman S., Schuetz P., Bent S. Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations. Export. Rev. Anti. Infect. Ther. 2011; 9: 727-735.
185. Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-460.
186. Niewoehner D.E., Erbland M.L., Deupree R.H., Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N. Engl. J. Med. 1999; 340: 1941-1947.
187. Leuppi J.D., Schuetz P., Bingisser R., Short-term vs. conventional glucocorticoid therapy in acute exacerbations of chronić obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309: 2223-2231.
188. Walters J.A., Gibson P.G., Wood-Baker R., Systemic corticosteroids for acute exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2009, CD001288.
189. Vollenweider D.J., Jarrett H., Steurer-Stay C.A., Antibiotics for exacerbations of chronić obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012 Dec 12; 12: CD010257.
190. Roede B.M., Bresser P., Bindels P.J., Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax 2008; 63: 968-973.
191. Ram F.S., Rodriguez-Roisin R., Granados-Navarrete A., Garcia- Aymerich J., Barnes N.C. WITHDRAWN: Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; 19: CD004403.
192. El Moussaoui R., Roede B.M., Speelman P., Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63: 415-22.
193. Hryniewicz W., Grzesiowski S., Kozielski J., Rekomendacje diagnostyki i leczenia zakażeń układu oddechowego. Warszawa 2008.
194. Burge P.S., Calverley P.M., Jones P.W., Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
195. Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902-1909.
196. Niewoehner D.E., Rice K., Cote C., Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143: 317-326.
197. Casaburi R., Mahler D.A., Jones P.W., A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.
198. Rennard S.I., Anderson W., ZuWallack R., Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092.
199. Aaron S.D., Vandemheen K.L., Fergusson D., Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-555.
200. Gorse G.J., O'Connor T.Z., Young S.L., Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest 2006; 130: 1109-1116.
201. Alfageme I., Vazquez R., Reyes N., Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61: 189-195.
202. Burtin C., Decramer M., Gosselinck R., Rehabilitation and acute exacerbations. Eur. Respir. J. 2011; 38: 702-711.
203. Washko G.R., Fan V.S., Ramsey S.D i wsp. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations Am. J. Respir. Crit. Care Med. 2008; 177: 164-169
204. Au D.H., Bryson C.L., Chien J.W., The effects of smoking cessation in the risk of chronic obstructive pulmonary disease exacerbations. J. Gen. Intern. Med. 2009; 24: 457-463.
205. Atsou K., Chouaid Ch., Hejblum G. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. PLOSone 2011; 6: e24870.
206. Solèr M., Mütterlein R., Cozma G. Swiss-German OM-85 Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007; 74: 26-32.
207. Sprenkle M.D., Niewoehner D.E., MacDonald R., Rutks I., Wilt T.J. Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. COPD 2005; 2: 167-175.
208. Walters J.A., Turnock A.C., Walters E.H., Wood-Baker R. Action plan with limited patients education only for exacerbations of chronic obstructive pulmonary disease. Cochrane Data Base Syst Rev 2010, CD005074.
209. Kunik M., Rondy K., Veazey C. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005; 127: 1205-1211.
210. Zhang M.W., Ho R.C., Cheunq M.W., Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen. Hosp. Psychiatr. 2011; 33: 217-223.
211. Hanania N.A., Müllerova H., Locantore N.W. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am. J. Respir. Crit. Care Med. 2011; 183: 604-611.
212. Bailey P. The dyspnea - anxiety - dyspnea cycle: COPD patients' stories of breathlessness. Qual. Health Res. 2004; 14: 760-778.
213. Gudmundsson G., Gislason T., Janson C. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur. Respir. J. 2005; 26: 414-419.
214. Dalal A.D., Shah M., Lunacsek O., Hanania N.A. Clinical and economic burden of depression/anxiety in chronić obstructive pulmonary disease patients within a managed care population. J. COPD 2011; 8: 293-299.
215. Voogd J., Wempe J., Koeter G., Depressive symptoms as predictors of mortality in patients with COPD. Chest 2009; 135: 619-625.
216. Knubben K., Reischies F.M., Adli M., A randomised controlled study on the effects of a short-term endurance training programme in patients with major depression. Br. J. Sports Med. 2007; 41: 29-33.
217. Harisson S.L., Greening N.J., Williams J.E., Have we underestimated the efficacy of pulmonary rehabilitation in improving mood? Respir. Med. 2011, Dec 22 article in press.
218. Curtis J.R., Engelberg R.A., Nielsen E.L., Au D.H., Patrick D.L. Patient-physician communication about end-of-life for patients with severe COPD. Eur. Respir. J. 2004; 24: 200-205.
219. Jones I., Kirby A., Ormiston P. The needs of patients dying of chronic obstructive pulmonary disease in the community. Fam. Pract. 2004; 21: 310-313.
220. O'Donnell D.E., Banzett R.B., Carrieri-Kohlman V., Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc. Am. Thorac. Soc. 2007; 4: 145-168.
221. Paz-Diaz H., Montes de Oca M., Lopez J.M., Celli B.R. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am. J. Phys. Med. Rehabil. 2007; 86: 30-36.
222. Gore J.M., Brophy C.J., Greenstone M.A. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000; 55: 1000-1006
223. Hung W.W., Visnivesky J.P., Siu A.L., Ross J.S. Cognitive decline among patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 134-137.
224. Budweiser S., Hitzl A.P., Jorres R.A., Health-related quality of life and long-term prognosis in chronic hypercapnic respiratory failure: a prospective survival analysis. Respir. Res. 2007; 8: 1-9.
225. Groft M. Palliative care in end-stage COPD. Brit. J. Gen. Pract. 2005; 55: 234-235.
226. Murray S.A., Kendall M., Boyd K., Sheikh A. Illness trajectories and palliative care. BMJ 2005; 330: 1007-1011.
227. Buchanan R.J., Chakravorty B., Wang S., Nursing home residents with emphysema/COPD compared to other residents. J. Soc. Work. Disabil. Rehabil. 2004; 3: 53-78.
228. Zalecenia Polskiego Towarzystwa Chorób Płuc dotycza{ogonek}ce opieki paliatywnej w przewlekłych chorobach płuc. Pneumonol. Alergol. Pol. 2012; 80: 41-64.